To tackle medication errors throughout the European Union, stakeholders in healthcare are being called upon to work together to improve reporting and prevention strategies. Collaboration is needed among national patient safety authorities, national competent authorities, the European Medicines Agency (EMA), the European Commission, patients, and healthcare professionals, concluded participants of a workshop on medication errors organised by EMA from 28 February 2013 – 1 March 2013.
Thomas Forissier favors an aggressive, comprehensive approach for tackling medication non-adherence, and for good reason. U.S. pharmaceutical companies are losing $188 billion each year because of non-adherence, according to analysis conducted by his firm, Capgemini Consulting, and by HealthPrize Technologies. “Money is being left on the table,” says Forissier, who serves as principal at Capgemini. “We were surprised at how high the numbers actually were.
Medical Device and Diagnostic Industry (MD+DI) and strategic alliance partner ITG Market Research, a division of ITG, recently published a landmark study on The Medical Device Outsourcing Landscape: Current & Future Trends, 2013-2018. The study represents the most popular trends, issues, and concerns shared by medical OEM professionals.
Antares Pharma, Inc. today announced that the New Drug Application (NDA) for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate (MTX) using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. OTREXUP is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application resubmission for STEDESA (eslicarbazepine acetate) for use as a once-daily adjunctive therapy in the treatment of partial-onset seizures in patients 18 years and older with epilepsy. STEDESA is the proposed trade name for eslicarbazepine acetate.
MedVantx Inc., the company that created the first ever controlled access to generic samples in US physician offices, today highlighted it's MedStart Connect program as a solution to the problem specified in a recent study published in JAMA Internal Medicine. In the study, researchers reported that changes in pill color that often occur during the prescription refill process significantly increase the odds of medication non-adherence.
Araxes Pharma LLC announced today it has entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against a certain target for the treatment of cancer.
Persistent Systems, the global leader in software product and technology services, today announced the immediate availability of PaxPharma, a compliance-based, Design to Print (D2P) automation solution designed specifically for pharmaceutical packaging and product lifecycle management (PLM). The company unveiled the solution at this year’s Pharma Packaging and Labeling USA 2013 conference being held February 26 and 27 at the Hilton Philadelphia City Avenue Hotel.
Persistent Systems, the global leader in software product and technology services, today announced the immediate availability of PaxPharma, a compliance-based, Design to Print (D2P) automation solution designed specifically for pharmaceutical packaging and product lifecycle management (PLM). The company unveiled the solution at this year’s Pharma Packaging and Labeling USA 2013 conference being held February 26 and 27 at the Hilton Philadelphia City Avenue Hotel.